OncoMatch/Clinical Trials/NCT06542250
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Is NCT06542250 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies AZD5492 for b-cell malignancies.
Treatment: AZD5492 — This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: CD20 overexpression (CD20+)
Histologically documented CD20+ mature B-cell neoplasm
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic stem cell transplant
Exception: within 180 days
Prior allogeneic HSCT within 180 days
Cannot have received: autologous stem cell transplant
Exception: within 90 days
prior autologous HSCT within 90 days
Cannot have received: cell therapy
Exception: within 90 days
cell therapy within 90 days of start of therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · La Jolla, California
- Research Site · Boston, Massachusetts
- Research Site · Hackensack, New Jersey
- Research Site · New York, New York
- Research Site · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06542250 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplant, autologous stem cell transplant, cell therapy disqualifies patients from enrollment.
Does this trial require CD20?
Yes, CD20 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify